Posted by Christ_empowered on September 18, 2015, at 12:35:28
In reply to FDA approves Vraylar for schizophrenia, bipolar, posted by Tomatheus on September 17, 2015, at 17:06:52
akathisia is rough, but I'm more concerned about movement disorders...why bring a drug to market if the TD risk is not much better than older drugs, or perhaps even worse than other "atypicals" ? That's not really progress.
That said...I got akathisia from Zyprexa, but not Abilify. Normal dopamine blockers--even the atypical ones--were/are problematic, but Abilify doesn't cause near as many problems.
So...there could be a subset of patients who need an AP and this could be just the thing for them, just like w/ Abilify some people who can't tolerate other drugs can tolerate Abilify.
I dunno. On the one hand, its good to have new drugs added, especially if they have at least somewhat unique mechanisms of action. On the other hand...Rx drugs are so weird. Its not a free market. You get what your doc prescribes and then somebody has to pay for it, somehow. So patients who might benefit may not get the Rx, patients who might want/need something else will get the Rx, and patients who need but can't afford it may have to stick w/ risperdal or something.
Ugh.
poster:Christ_empowered
thread:1082598
URL: http://www.dr-bob.org/babble/20150901/msgs/1082649.html